Product image of Menveo (Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, N. M) supplied by GNH India

Menveo

Active Ingredient:
Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, N. M
Origin:
EU

Menveo (Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, N. M)

Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, the active ingredient in Menveo, is a vaccine presented as a 0.5 mL vial (lyophilized powder for suspension) for intramuscular use. It induces protective immunity against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W‑135 and Y in at‑risk populations, including children, adolescents and adults.

GNH India supplies Menveo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable cold‑chain logistics across global markets.

Manufacturer / TM Owner

Gsk Vaccines S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Menveo is a conjugate vaccine targeting the capsular polysaccharides of Neisseria meningitidis and is used for prevention of meningococcal disease.

  • Invasive meningococcal disease (serogroups A, C, W‑135, Y): Provides active immunity to reduce the risk of infection.
  • Adolescents and young adults: Lowers incidence of meningococcal disease in high‑risk age groups.
  • Travelers to endemic regions: Offers protection against meningococcal infection during international travel.

How It Works

  • Menveo contains polysaccharides from Neisseria meningitidis serogroups A, C, W‑135 and Y covalently linked to the non‑toxoid protein carrier CRM197. The conjugate format enables a T‑cell‑dependent response, prompting B‑cells to produce high‑affinity, long‑lasting antibodies against the bacterial capsular polysaccharides, and generates memory B‑cells for rapid protection upon exposure.

Side Effects

Common and serious adverse reactions have been reported following Menveo administration.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Fever: transient elevation of body temperature.
  • Headache: mild headache occurring within 24 hours.
  • Fatigue: temporary feeling of tiredness.
  • Muscle aches: mild myalgia around the injection area.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurologic disorder reported post‑vaccination.
  • Seizures: infrequent occurrence, especially in febrile children.
  • Hypotension: sudden drop in blood pressure after injection.
  • Meningococcal disease despite vaccination: extremely rare breakthrough infection.

Precautions & Warnings

Before administering Menveo, consider the following precautions and warnings.

  • Pregnancy: safety not established; vaccinate only if benefit outweighs risk.
  • Immunocompromised patients: vaccine may elicit a reduced immune response.
  • Known allergy: avoid if hypersensitivity to any vaccine component, including CRM197.
  • Fever monitoring: observe for fever or systemic reactions after injection.
  • Concurrent vaccines: can be given at separate sites; follow recommended intervals.
  • Storage: Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Menveo may interact with other medicines or biologics; consider the following.

Major Interactions (Avoid)

  • Live bacterial vaccines: avoid simultaneous administration as immune response may be impaired.
  • Immunoglobulin therapy: may diminish vaccine efficacy if given concurrently.

Moderate Interactions (Monitor Closely)

  • Antipyretics (e.g., acetaminophen): may mask post‑vaccination fever, monitor temperature.
  • Other vaccines: schedule appropriately to avoid interference with immune response.
  • Immunosuppressive drugs: monitor antibody levels as response may be attenuated.
  • Blood products: consider timing to prevent reduced immunogenicity.

Frequently Asked Questions

Menveo is a conjugate vaccine indicated for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W‑135 and Y. It is administered to individuals at risk, including children, adolescents, adults, and travelers to endemic areas.

The active ingredient consists of polysaccharides from four meningococcal serogroups chemically linked to the CRM197 protein carrier. This conjugation creates a T‑cell‑dependent immune response, stimulating B‑cells to produce high‑affinity antibodies and memory cells that protect against future infection.

The dosing schedule for Menveo is determined by the prescribing healthcare professional based on age, risk factors and local immunization guidelines. The vaccine is supplied as a lyophilized powder that must be reconstituted and given as a single intramuscular injection per the prescriber's instructions.

Safety data for Menveo in pregnant or breastfeeding individuals are limited. The vaccine should only be administered during pregnancy if the potential benefit justifies any possible risk, and healthcare providers should discuss individual circumstances with the patient.

To order Menveo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Menveo is a quadrivalent conjugate vaccine covering serogroups A, C, W‑135 and Y, similar to other products such as Nimenrix or Menactra. All use a protein carrier to enhance immunogenicity, but differences may exist in carrier protein, dosing schedule, and regulatory approvals in specific regions.

Menveo must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. After reconstitution, the suspension should be used immediately and discarded if not used within the recommended time.

Menveo is supplied as a lyophilized powder that is reconstituted with the provided diluent to form a clear suspension. The vaccine is then administered as a single intramuscular injection, typically in the deltoid muscle, by a qualified healthcare professional.

Serious adverse events reported with Menveo include anaphylaxis, Guillain‑Barré syndrome, seizures (especially in febrile children), severe hypotension, and, rarely, breakthrough meningococcal disease despite vaccination. Any signs of severe allergic reaction or neurologic symptoms should be evaluated promptly.

Menveo is contraindicated in individuals with a known severe allergy to any component of the vaccine, including the CRM197 carrier protein. Persons who have experienced a previous severe reaction to a meningococcal conjugate vaccine should also avoid further doses.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, N. M

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT